Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

for standing by. Welcome to the ADEX Therapeutics Third Quarter 2025 Financial Results and Corporate Update Conference Call and Webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be the question and answer session. To ask a question during the session, you need to press star, one, one on your telephone keypad. You will then hear an automatic message advising your hand is raised. To withdraw a question, please press star, one, and one again. If you wish to ask a question via the webcast, please use the Q&A box available on the webcast link anytime during the live event. Please be advised that this conference is being recorded. I would now like to hand the conference over to our third speaker today, Tim Dyer, CEO. Please go ahead. Thank you. Hello, everyone. I'd like to thank you all for attending our third quarter 2025 financial conference call. I'm here with Misha Kalinchev, our Head of Translational Science, who will be providing an update on our R&D program. I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha, who will review in more detail our post-stroke recovery program and gather the PAM preclinical program for cost. I will then review our Q3 2025 financial results. Following that, we will open the call for Q&A. The third quarter of 2025 has seen several important achievements across our pipeline. We've made excellent pr...